Activity

Latest NCCN guidelines for TKI discontinuation published, “With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia (CML) in the chronic phase, who achieve and maintain a major molecular response (MMR), according to version 1.2019 of the CML management guideline from the National Comprehensive Cancer Network (NCCN).”

Patients must partner with a CML specialty center to discuss the risks of TKI discontinuation (TKI withdrawal, relapse, etc.), determine their eligibility, and if moving forward to make a plan for close monitoring during TKI discontinuation. About half of all patients attempting to stop TKI treatment after maintenance of MMR remain in treatment-free remission after 5 years.

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline

https://www.onclive.com/conference-coverage/nccn-2019/tki-discontinuation-criteria-established-in-updated-nccn-cml-guideline

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.